CLARITY Extension Study

NCT00641537 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

867

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Cladribine
DRUG: Placebo
DRUG: Cladribine
DRUG: Cladribine
DRUG: Placebo

Sponsor

EMD Serono Research & Development Institute, Inc.